Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)

Completed · Phase 1

Conditions studied: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting

In brief

Objective: The primary goal of this study is to investigate the mechanism of action (MOA) of CD25-blocking therapies in high inflammatory multiple sclerosis (HI-MS). The secondary goal of this study is to assess long-term safety and efficacy of CD25-blocking therapies in HI-MS. Study population: Two cohorts of patients will be enrolled: * Long-term daclizumab therapy cohort: Up to 15 daclizumab-treated patients with relapsing-remitting (RR-MS) or secondary-progressive MS (SP-MS) previously classified as HI-MS based on MRI/clinical criteria, who have been treated with IV daclizumab for a minimum of 1 year and responded to this therapy with significant (\>70%) decrease in contrast-enhancing lesions (CEL) or stabilization/improvement of disease activity (\>60% decrease in MS relapses and stable or improved EDSS disability score). * New treatment cohort: Up to 15 HI-MS patients (RR- or SP-MS) with inadequate therapeutic response to first-line, FDA-approved immunomodulatory therapies for MS or who cannot, for any reason, be treated with first-line, FDA-approved immunomodulatory therapies for MS. Design: This is an open label, Phase I trial of 150 mg of daclizumab high yield process (DAC HYP) administered subcutaneously (SC) every 4 weeks for a total of 3 years. Outcome measures: Because the main goal of this study is to investigate the MOA of CD25-blocking therapies in MS, the primary outcomes are mechanistic immunological studies performed on clinical samples (peripheral blood mononuclear cells (PBMC), cerebrospinal fluid (CSF) cells and skin biopsies) derived from DAC HYP-treated patients. The secondary outcome measure is long-term safety and tolerability of subcutaneous DAC HYP in HI-MS patients.

Key facts

Study ID

NCT01143441

Run by

National Institute of Neurological Disorders and Stroke (NINDS)

People needed

48

Starts

2010-05-13

Expected to finish

2017-08-11

Last updated by the study team

2019-11-01

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• MS as defined by the modified McDonald criteria (Polman, Reingold et al. 2005)
• HI-MS (RR-MS or SP-MS) before initiation of daclizumab therapy, defined as:
• greater than or equal to 3 CEL on a single pre-daclizumab MRI or
• greater than or equal to 1 MS exacerbation per year before initiation of daclizumab therapy or
• progression of sustained disability by greater than or equal to 1.0 point on the expanded disability status scale (EDSS) in the year preceding daclizumab therapy
• Age 18-60, inclusive
• EDSS 0 to 6.0, inclusive
• Able to provide informed consent
• Willing to participate in all aspects of trial design and follow-up
• Females of childbearing potential are willing to commit to the use of a reliable method of birth control (i.e., hormonal contraception including birth control pills, injected hormones or vaginal ring; intrauterine device; barrier methods with spermicide, specifically diaphragms or condoms they have undergone surgical sterilization, such as hysterectomy or tubal ligation) for the duration of the study and continued 4 months after conclusion of the study.
• ADDITIONAL INCLUSION CRITERION FOR THE LONG-TERM DACLIZUMAB THERAPY COHORT ONLY:
• IV daclizumab therapy for at least 1 year with a treatment response consisting of:<TAB>
• greater than or equal to 70% reduction of CEL after starting daclizumab; or
• stabilization or improvement of sustained neurological disability on daclizumab.
• EXCLUSION CRITERIA (FOR BOTH COHORTS):
• PP-MS or low-inflammatory SP-MS
• Alternative diagnoses that can explain neurological disability and MRI findings (e.g., ischemia/gliosis, CNS lyme disease, SLE, sarcoidosis, etc.)
• History of malignancy, with the following exceptions: excised or treated basal cell carcinoma or fewer than 3 squamous cell carcinomas, grade 1 endometrial carcinomas treated with total hysterectomy and without evidence for recurrence for greater than or equal to 3 years
• Clinically significant medical disorders that, in the judgment of the investigators, could cause CNS tissue damage or limit its repair, expose the patient to undue risk of harm or prevent the patient from completing the study (e.g., immunodeficiency disorders, other autoimmune or immune-mediated disorders or chronic infections). Specific exclusions (based on baseline laboratory evaluation) are:
• positive HIV or HTLV-1 serology;
• positive hepatitis B or C serology;
• pregnant or breastfeeding female;
• known history of severe allergic or anaphylactic reactions;
• known hypersensitivity to study drug or its excipients;
• varicella or herpes zoster virus infection or any severe viral infection within the 6 weeks prior to screening; or

Where it is running

• National Institutes of Health Clinical Center, 9000 Rockville Pike — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.